Royal Fund Management LLC Has $900,000 Stake in Moderna, Inc. (NASDAQ:MRNA)

Royal Fund Management LLC reduced its holdings in Moderna, Inc. (NASDAQ:MRNA) by 39.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 9,045 shares of the company’s stock after selling 5,900 shares during the quarter. Royal Fund Management LLC’s holdings in Moderna were worth $900,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. The Manufacturers Life Insurance Company increased its position in Moderna by 77.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after buying an additional 1,690,341 shares during the period. Invesco Ltd. raised its stake in Moderna by 19.8% during the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after purchasing an additional 517,683 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Moderna by 9.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company’s stock valued at $579,572,000 after purchasing an additional 476,201 shares during the period. Bamco Inc. NY grew its position in Moderna by 4,863.6% in the 3rd quarter. Bamco Inc. NY now owns 426,869 shares of the company’s stock worth $44,091,000 after purchasing an additional 418,269 shares during the last quarter. Finally, abrdn plc increased its holdings in shares of Moderna by 477.5% during the 4th quarter. abrdn plc now owns 483,574 shares of the company’s stock worth $48,091,000 after purchasing an additional 399,843 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Down 0.5 %

Shares of MRNA traded down $0.59 during mid-day trading on Friday, hitting $125.00. 4,513,133 shares of the company’s stock were exchanged, compared to its average volume of 3,445,723. The company has a 50-day simple moving average of $105.05 and a 200 day simple moving average of $94.37. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.36. The company has a market cap of $47.86 billion, a PE ratio of -7.98 and a beta of 1.57. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $142.79.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. During the same period in the previous year, the business earned $0.19 EPS. The company’s revenue was down 91.0% compared to the same quarter last year. On average, research analysts forecast that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MRNA has been the subject of several research reports. HSBC reiterated a “reduce” rating and issued a $86.00 target price (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Canaccord Genuity Group boosted their price objective on Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a research report on Friday. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Thursday. Royal Bank of Canada increased their price objective on shares of Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Oppenheimer lifted their target price on shares of Moderna from $142.00 to $163.00 and gave the company an “outperform” rating in a research report on Friday. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Moderna presently has an average rating of “Hold” and an average target price of $129.55.

Insider Buying and Selling

In other news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total value of $1,663,800.00. Following the completion of the sale, the director now owns 2,026,931 shares of the company’s stock, valued at approximately $224,827,186.52. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the transaction, the director now directly owns 2,026,931 shares in the company, valued at approximately $224,827,186.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Shannon Thyme Klinger sold 670 shares of the firm’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $63,361.90. Following the completion of the sale, the insider now owns 8,557 shares of the company’s stock, valued at $809,235.49. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 139,954 shares of company stock worth $14,822,576. Corporate insiders own 15.70% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.